|[March 22, 2013]
Research and Markets: Norvir (HIV) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/5bf4z9/norvir_hiv)
has announced the addition of the "Norvir
(HIV) - Forecast and Market Analysis to 2022" report to their
Norvir (ritonavir) is a PI indicated in combination with other
antiretroviral agents for the treatment of HIV infection. Unlike most
PIs, which are prescribed due to their activity against the HIV
protease, Norvir is commonly prescribed in combined with other protease
inhibitors as a pharmacokinetic enhancer. Norvir increases the plasma
levels of other PIs by inhibiting the cytochrome P450 enzyme CYP3A,
which would otherwise decrease bioavailability and half-life of the PIs
via metabolism (Norvir prescribing information, 2012). Therefore, while
Novir can be administered as an antiretroviral agent, the drug will be
considered as a pharmacokinetic enhancer for the purposes of this report
since the drug is predominately prescribed for that purpose.
Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has
claimed millions of lives since its emergence. However, the advent of
antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a
deadly disease to a manageable chronic condition for most infected
individuals. Antiretroviral treatment not only reduces the viral load
and reconstitutes immune function, but also decreases infection
incidence rates by limiting viral transmission. The treatment algorithm
in HIV has characteristically involved multiple drug regimens designed
to tackle the virus on different levels. In the recent past, simplified
dosing regimens through the emergence of single tablet regimens (STRs)
or fixed dose combination (FDC) therapies have become increasingly
popular amongst physicians and patients alike by increasing clinical
efficacy thresholds and enabling patient compliance.
- Overview of HIV, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on
the competitive landscape.
- Detailed information on Norvir including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Norvir for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan, Brazil and China
For more information visit http://www.researchandmarkets.com/research/5bf4z9/norvir_hiv
[ InfoTech Spotlight's Homepage ]